EU Approved Signifor, Novartis’ New Acromegaly Drug

November 24, 2014 3:04 PM

4 0

On Monday, Signifor – Novartis’ newest drug aimed at treating a rare hormonal disorder called acromegaly – was approved by the European Union. Signifor is now available in 27 European member states, including Iceland and Norway. An application for Signifor’s approval had been also currently filed in the US.

The European Commission’s approval for Novartis’ new acromegaly drug was mainly based on two clinical trials (C2402 and C2305) that showed significant improvements Signifor brought to acromegaly patients.

Read more

To category page